In an in vivo study using a testosterone-induced BPH rat model, the administration of PA (40 mg/kg) for four weeks decreased prostatic weight by 19% and decreased the serum and prostate levels of myeloperoxidase activities and nitrate oxide, which are reliable markers of the degree of inflammation and oxidative stress [128]. Here, MPO is linked to benign prostatic hyperplasia.